NCT03331484 (CAPITAL PCI AF) is a Phase 3 clinical trial of Ticagrelor in Atrial Fibrillation, sponsored by Ottawa Heart Institute Research Corporation.

Who is sponsoring NCT03331484?

NCT03331484 is sponsored by Ottawa Heart Institute Research Corporation.

What drugs are being tested in NCT03331484?

Interventions in NCT03331484: Ticagrelor, Rivaroxaban.

What condition does NCT03331484 study?

NCT03331484 studies Atrial Fibrillation, Acute Coronary Syndrome.

Is NCT03331484 still recruiting?

NCT03331484 is currently status unknown. Last updated 17 January 2023.

Last reviewed 2023-01-17 · How we verify

NCT03331484: CAPITAL PCI AF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Safety and Efficacy Of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention

Status unknown Phase 3 Last updated 17 January 2023

What this trial tests

Phase 3 trial testing Ticagrelor in Atrial Fibrillation in 40 participants. Status unknown.

Timeline

1 November 2018

Primary endpoint
1 November 2023

15 December 2023

Quick facts

Lead sponsor	Ottawa Heart Institute Research Corporation
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	40
Start date	1 November 2018
Primary completion	1 November 2023
Estimated completion	15 December 2023
Sites	1 location across Canada

Drugs / interventions tested

Ticagrelor (ticagrelor) — full drug profile →
Rivaroxaban (rivaroxaban) — full drug profile →

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →
Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →

Sponsor

Ottawa Heart Institute Research Corporation

Who can join

18 and older, any sex, with Atrial Fibrillation or Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Currently, there is minimal data on the combination of rivaroxaban and ticagrelor in patients with atrial fibrillation (AF) managed with percutaneous coronary intervention (PCI). Furthermore, there exists significant controversy among physicians in the use of oral anticoagulants in conjunction with antiplatelet therapy in this population. The present recommendation is triple therapy (aspirin + clopidogrel + warfarin), which has been related to major bleeding complications. Previous studies have shown that ticagrelor has been proven to be more effective in reducing the rate of death, new heart attacks, or strokes than the previously recommended drug, clopidogrel, and studies have shown that less bleeding occurs with rivaroxaban than with warfarin. Therefore, it would be ideal to investigate the two potent drugs, ticagrelor and rivaroxaban, in combination in order to gain insight in the management of these high-risk patients. The CAPITAL PCI AF study is a phase 3 Health Canada regulated interventional study involving the use of investigational drugs. It is a non-randomized, open-design study. The investigational team is studying the highly potent drug Ticagrelor, which is prescribed to participants receiving a stent placement, given in combination with Rivaroxaban, an oral anticoagulant recommended for patients with AF. The primary clinical endpoint is a safety outcome measuring bleeding complications in participants with AF treated within one year of the index PCI. The primary efficacy endpoint is measured by the clinical outcomes of death, stroke, non-central nervous system systemic embolism, myocardial infarction, and stent thrombosis within one year of the index PCI.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Platelet biology and function: plaque erosion vs. rupture.
Baaten CCFMJ, Nagy M, Bergmeier W, Spronk HMH, et al · · 2024 · cited 70× · PMID 37940193 · DOI 10.1093/eurheartj/ehad720

Verify or expand the search:

Other trials of Ticagrelor

Trials testing the same drug.

NCT06451198 — IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome · Phase 4 · recruiting
NCT07358416 — Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery. · active not recruiting
NCT06584812 — Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects · Phase 1 · completed
NCT06554821 — A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy · Phase 1 · completed
NCT06301776 — A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy · NA · recruiting

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other Ottawa Heart Institute Research Corporation trials

Trials by the same sponsor.

NCT06907251 — Dapagliflozin for Long COVID Syndrome · Phase 3 · not yet recruiting
NCT07002450 — Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Departm · NA · recruiting
NCT06832085 — Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation · Phase 4 · recruiting
NCT06556667 — MAX - SHOCK Clinical Trial · NA · recruiting
NCT06816888 — Impact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03331484 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ottawa Heart Institute Research Corporation
Last refreshed: 17 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03331484.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing